Publication
Background: The development of therapeutics for Parkinson's disease (PD) requires the establishment of biomarker assays to enable stratifying patients, monitoring disease progression, and assessing target engagement. Attempts to develop diagnostic assays based on detecting levels of the alpha-synuclein (alpha SYN) protein, a central player in the pathogenesis of PD, have yielded inconsistent results.
Henning Paul-Julius Stahlberg, Amanda Jennifer Lewis, Domenic Burger, Marta Di Fabrizio, Carolin Böing
Silvio Canonica, Urs von Gunten, Stephanie Christa Remke, Joanna Maria Houska